The abstract is read at the publisher; the summary is JClub's.
BRD5529 (1 mg/kg) reduces Pneumocystis murina lung organism burden in mice with established PCP, with a magnitude similar to TMP-SMX therapy.
- Why it matters: CARD9-driven innate signaling is central to host defense in Pneumocystis pneumonia, but excessive inflammation can also worsen lung injury.
- What they did: Mice with established PCP received BRD5529 (1 mg/kg), and P. murina burden was measured; parallel ex vivo tests used precision-cut lung slices infected with P. murina and treated for 72 h.
- The result: In PCLS, BRD5529 lowered P. murina viability after 72 h, with the largest reduction at lower drug concentrations, while resazurin-based metabolic activity and viability were not reduced.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.